99 related articles for article (PubMed ID: 28464260)
61. ENPP1, an Old Enzyme with New Functions, and Small Molecule Inhibitors-A STING in the Tale of ENPP1.
Onyedibe KI; Wang M; Sintim HO
Molecules; 2019 Nov; 24(22):. PubMed ID: 31752288
[TBL] [Abstract][Full Text] [Related]
62. Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast Cancer.
Kawaguchi M; Han X; Hisada T; Nishikawa S; Kano K; Ieda N; Aoki J; Toyama T; Nakagawa H
J Med Chem; 2019 Oct; 62(20):9254-9269. PubMed ID: 31536342
[TBL] [Abstract][Full Text] [Related]
63. Angiogenesis and evading immune destruction are the main related transcriptomic characteristics to the invasive process of oral tongue cancer.
Pérez-Valencia JA; Prosdocimi F; Cesari IM; da Costa IR; Furtado C; Agostini M; Rumjanek FD
Sci Rep; 2018 Jan; 8(1):2007. PubMed ID: 29386520
[TBL] [Abstract][Full Text] [Related]
64. Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis.
Trapero C; Jover L; Fernández-Montolí ME; García-Tejedor A; Vidal A; Gómez de Aranda I; Ponce J; Matias-Guiu X; Martín-Satué M
Am J Reprod Immunol; 2018 Feb; 79(2):. PubMed ID: 29194839
[TBL] [Abstract][Full Text] [Related]
65. The metabolic role of the CD73/adenosine signaling pathway in HTR-8/SVneo cells: A Double-Edged Sword?
Song G; Zhang D; Zhu J; Wang A; Zhou X; Han TL; Zhang H
Heliyon; 2024 Feb; 10(3):e25252. PubMed ID: 38322906
[TBL] [Abstract][Full Text] [Related]
66. Purinergic signaling: Diverse effects and therapeutic potential in cancer.
Kaur J; Dora S
Front Oncol; 2023; 13():1058371. PubMed ID: 36741002
[TBL] [Abstract][Full Text] [Related]
67. Targeting purine metabolism in ovarian cancer.
Liu J; Hong S; Yang J; Zhang X; Wang Y; Wang H; Peng J; Hong L
J Ovarian Res; 2022 Aug; 15(1):93. PubMed ID: 35964092
[TBL] [Abstract][Full Text] [Related]
68. Adenosine Receptor A2B Negatively Regulates Cell Migration in Ovarian Carcinoma Cells.
Campos-Contreras ADR; González-Gallardo A; Díaz-Muñoz M; Vázquez-Cuevas FG
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562985
[TBL] [Abstract][Full Text] [Related]
69. Generation of a Retargeted Oncolytic
Gentile C; Finizio A; Froechlich G; D'Alise AM; Cotugno G; Amiranda S; Nicosia A; Scarselli E; Zambrano N; Sasso E
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948316
[TBL] [Abstract][Full Text] [Related]
70. Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance.
Bednarska-Szczepaniak K; Przelazły E; Kania KD; Szwed M; Litecká M; Grűner B; Leśnikowski ZJ
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359756
[TBL] [Abstract][Full Text] [Related]
71. Autocrine and paracrine purinergic signaling in the most lethal types of cancer.
Reyna-Jeldes M; Díaz-Muñoz M; Madariaga JA; Coddou C; Vázquez-Cuevas FG
Purinergic Signal; 2021 Sep; 17(3):345-370. PubMed ID: 33982134
[TBL] [Abstract][Full Text] [Related]
72. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer.
Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J
Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385
[TBL] [Abstract][Full Text] [Related]
73. Purinergic Signaling in the Hallmarks of Cancer.
Campos-Contreras ADR; Díaz-Muñoz M; Vázquez-Cuevas FG
Cells; 2020 Jul; 9(7):. PubMed ID: 32635260
[TBL] [Abstract][Full Text] [Related]
74. Increased Purinergic Responses Dependent on P2Y2 Receptors in Hepatocytes from CCl
Velázquez-Miranda E; Molina-Aguilar C; González-Gallardo A; Vázquez-Martínez O; Díaz-Muñoz M; Vázquez-Cuevas FG
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225112
[TBL] [Abstract][Full Text] [Related]
75. CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer.
Xu Z; Gu C; Yao X; Guo W; Wang H; Lin T; Li F; Chen D; Wu J; Ye G; Zhao L; Hu Y; Yu J; Shi J; Li G; Liu H
Cell Death Dis; 2020 Mar; 11(3):202. PubMed ID: 32205841
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.
Azambuja JH; Ludwig N; Braganhol E; Whiteside TL
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739402
[TBL] [Abstract][Full Text] [Related]
77. Cellular Migration Ability Is Modulated by Extracellular Purines in Ovarian Carcinoma SKOV-3 Cells.
Martínez-Ramírez AS; Díaz-Muñoz M; Battastini AM; Campos-Contreras A; Olvera A; Bergamin L; Glaser T; Jacintho Moritz CE; Ulrich H; Vázquez-Cuevas FG
J Cell Biochem; 2017 Dec; 118(12):4468-4478. PubMed ID: 28464260
[TBL] [Abstract][Full Text] [Related]
78. The P2RY2 Receptor Induces Carcinoma Cell Migration and EMT Through Cross-Talk With Epidermal Growth Factor Receptor.
Martínez-Ramírez AS; Garay E; García-Carrancá A; Vázquez-Cuevas FG
J Cell Biochem; 2016 Apr; 117(4):1016-26. PubMed ID: 26443721
[TBL] [Abstract][Full Text] [Related]
79. 1α,25(OH)₂D₃ Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelial-Mesenchymal Transition.
Hou YF; Gao SH; Wang P; Zhang HM; Liu LZ; Ye MX; Zhou GM; Zhang ZL; Li BY
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548154
[TBL] [Abstract][Full Text] [Related]
80. Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition.
Teng L; Peng S; Guo H; Liang H; Xu Z; Su Y; Gao L
Cancer Gene Ther; 2015 Nov; 22(11):518-23. PubMed ID: 26494557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
